Health TrialsbyHealthPanel

Stratifying Critically Ill Patients for Novel Ferroptosis or Pyroptosis Intervention Strategies

ConditionsSepsisTrauma Related InjuriesSubarachnoid Haemorrhage (SAH)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Antwerp

About this trial

In order to better determine which therapy is best for patiënts which present with organ falure during the course of their stay in the intesive care unit (ICU) , one has to determine which underlying mechanism is causing this organ falure. We will determine levels of so called "biomarkers" for ferroptosis (a mechan ism of iron-related cell death) in the peripheral blood and biological fluids of criticaly ill patients admitted to the ICU with a catastrrophy (severe infection, trauma ...) . Why ? If it turns out that this ferroptosis plays a role in the ocurrence of organ failure in the critially ill, this will lead to new therapies in the future as drugs become more and more available which can influene this biochemical "pahway". of iron-relatd death.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Admitted to the ICU of UZA

Critically ill and predicted to be hospitalised in the ICU for > 48 hours (i.e. mostly patients admitted for sepsis, trauma, haemorrhagic shock, neurological catastrophe … which means at risk to develop mono-or multiple organ failure)

With arterial line in place (for blood sampling)

Disqualifiers

Refusal of consent by patient or closest relative

Postoperative patients after major surgery in whom prolonged ICU stay is not foreseen (i.e. elective cardiac surgery

Trial design

Design model

Single group

Treatments tested in this trial

  • Blood sampling

    Diagnostic test

    Blood sampling: 3 first days of admision, 2 ml of plasma daily Urine, BALF, CSF sampling: 1 day during 3 first days of admission

Treatment groups

600 Participants
are divided into 1 treatment group
Group A: Critical illnessExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Number of patients with survival after 28 days.

Survival in and after ICU.

Time frame
28 days

Secondary outcomes

1

Change from baseline concentration of Norepinephrine every day during ICU stay

Time frame
28 days
2

Change in SOFA score during ICU stay

SOFA score, with a higher score for more severe organ failure

Time frame
Change from enrollment to 14 days of ICU stay

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Antwerp

Lead sponsor

Universiteit Antwerpen

Collaborator

Source ClinicalTrials.gov
Apply now